Evidence map›Paper›PMID 18718871›Full record

Trial reportNeuroImage2008

Serotonin transporter genotype and depressive phenotype determination by discriminant analysis of glucose metabolism under acute tryptophan depletion.

Allison C Nugent, Alexander Neumeister, David Goldman, Peter Herscovitch, Dennis S Charney, Wayne C Drevets

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in NeuroImage, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Allison C NugentSection on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, NIH, Bethesda, MD 20892-0940, USA. nugenta@mail.nih.gov
Alexander Neumeister
David Goldman
Peter Herscovitch
Dennis S Charney
Wayne C Drevets
National Institute of Mental Health · USIcahn School of Medicine at Mount Sinai · USNational Institute on Alcohol Abuse and Alcoholism · USPositron (United States) · USYale University · US

Funding

Integrative genetics with high throughput, multiplex genZ01AA000301 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GOLDMAN, DAVID · 1999 to 2008
$5.2M
Tryptophan Depletion in Remitted Depressed PatientsZ01MH002817 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI DREVETS, WAYNE C · 2003 to 2008
$912k
Tryptophan Depletion in Remitted Depressed PatientsZIAMH002817 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI DREVETS, WAYNE C · 2009 to 2009
$373k
Gene-Environment Interations Underlying Alcoholism Vulnerability DisordersZ01AA000306 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GOLDMAN, DAVID · 2006 to 2008
$122k
Intramural NIH HHS Z01 AA000301Intramural NIH HHS Z01 AA000306Intramural NIH HHS Z01 MH002817Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

Acute tryptophan depletion (ATD) putatively results in a transient reduction in central serotonin transmission, and induces depressed mood in some un-medicated subjects with remitted major depressive disorder (MDD). The 5-HT transporter promoter region length polymorphism (5-HTTLPR) has been shown to influence behavioral and metabolic responses to ATD, as well as the risk for developing MDD within the context of stress. The current study investigates the relationships between 5-HTTLPR genotype, neurophysiologic response to ATD, and diagnostic phenotype (healthy control subjects versus MDD subjects differentiated by their depressive response to ATD) using (18)FDG-PET. Un-medicated subjects with remitted MDD and healthy controls were genotyped for the long (l) and short (s) alleles of the 5-HTTLPR polymorphism and categorized into one of three genotypes. On two separate occasions, subjects received either a placebo or an amino acid mixture designed to deplete plasma tryptophan, followed by (18)FDG-PET scanning. Depressive symptoms were rated to determine the diagnostic phenotype. Descriptive and predictive discriminant analyses were performed using brain regional metabolic data to classify according to phenotype and genotype. Overall, 79% of the cases were classified correctly by genotype, and 85% were classified correctly by phenotype. In a leave-one-out cross-validation, 72% of the subjects were classified correctly as carrying an s-allele, and 79% of the subjects were classified correctly by primary diagnosis. The robust nature of the classification results indicates that much of the variance in metabolic response to ATD is accounted for by genotypic and phenotypic category.

Indexed as

AdultBrainDepressionDiscriminant AnalysisFemaleFluorodeoxyglucose F18Genetic Predisposition to DiseaseGlucoseHumansMalePhenotypePlacebo EffectPositron-Emission TomographyRadiopharmaceuticalsSerotonin Plasma Membrane Transport ProteinsTryptophanFluorodeoxyglucose F18GlucoseRadiopharmaceuticalsSerotonin Plasma Membrane Transport ProteinsTryptophan

Identifiers

PMID18718871
PMCPMC2650221
OpenAlexW1982697004

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.